🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

VTX002 shows promise in ulcerative colitis trial

EditorEmilio Ghigini
Published 22/02/2024, 11:22 pm
© Reuters.
VTYX
-

SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ: VTYX), a biopharmaceutical company engaged in developing novel oral therapies for inflammatory diseases, has announced results from the Phase 2 trial of its drug candidate VTX002. The findings were presented at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm, Sweden.

The study focused on VTX002, an oral selective sphingosine-1-phosphate-1 receptor modulator, and its efficacy and safety in treating moderately to severely active ulcerative colitis. The trial was randomized, double-blind, and placebo-controlled, aiming to establish VTX002 as a potential oral treatment option with a favorable safety profile.

Raju Mohan, CEO of Ventyx, expressed optimism about the drug's profile, citing a "potentially differentiated rate of endoscopic remission and histologic-endoscopic mucosal improvement" as well as its potential for being a best-in-class safety option.

The presentation, led by Dr. Bruce E. Sands of the Icahn School of Medicine at Mount Sinai, NY, discussed the outcomes of the trial, which could represent a significant development for patients with ulcerative colitis, a chronic inflammatory bowel disease.

While Ventyx has cautioned against placing undue reliance on forward-looking statements, the company has underscored its commitment to addressing unmet medical needs through the development of oral immunology therapies. Ventyx's pipeline includes other internally discovered clinical programs targeting various immune-related pathways.

The results from the trial are expected to contribute to the ongoing research and development efforts in the field of autoimmune and inflammatory disorders. Ventyx's focus remains on providing novel oral treatments that could potentially transition immunology markets from injectable to oral drugs.

The data from the VTX002 trial is now available in the Investors section of Ventyx's website. The company continues to navigate the challenges of clinical development, including the inherent risks and uncertainties of trial outcomes and regulatory processes.

This report is based on a press release statement from Ventyx Biosciences, Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.